Lung Cancer

But analysis does suggest a small increase in risk for individuals who used cigarettes and electronic nicotine delivery systems together.

The application is based on the PHAROS trial, which met its primary endpoint of objective response rate in patients with metastatic non–small cell lung cancer with a BRAF V600E mutation.

Experts note that pharmacists are well positioned to play a key role in precision oncology and molecular tumor boards.

Historically, there are many hard-to-treat mutations of non-small cell lung cancer.

Among patients with lung cancer, approximately 20% have the earliest stage of disease but are still dying of metastatic lung cancer within about 5 years.

Blinded arms of the study will continue to evaluate the combination therapy with docetaxel vs docetaxel alone, Merck says.

The treatment shows an acceptable toxicity profile and no new adverse events, according to results of analysis.

Osimertinib (Tagrisso; AstraZeneca) now has shown a statistically significant and clinically meaningful overall survival benefit in both the early adjuvant and late-stage metastatic settings.

Adding durvalumab to neoadjuvant chemotherapy to treat resectable early-stage non–small cell lung cancer did not increase complications and adverse events or comprise patients’ ability to undergo surgery versus chemotherapy alone.

Median overall survival was also 2 months less for patients with extensive-stage small cell lung cancer who were ineligible for clinical trials.

The KEYNOTE-641 and -789 trials did not demonstrate improvements or meet the primary endpoints in metastatic castration-resistant prostate cancer and metastatic nonsquamous non–small cell lung cancer.

Ventana PD-L1 (SP263) Assay can increase access to cemiplimab and improve patient outcomes in non-small cell lung cancer.

Atrial fibrillation and atherosclerotic cardiovascular disease are frequent challenges among patients with cancer.

Pembrolizumab showed statistically significant improvement in the event-free survival of patients with resectable stage 2 or 3 non-small cell lung cancer.

An expert shares information on risk factors and controversies around testing.

Both indications for the CTLA-4 inhibitor were approved by the FDA in 2022.

Investigators hope that new findings can cultivate new methods of facilitating immune response to attack lung tumors.

In the United States, 91% of states had lower rates of targeted therapy use than expected.

Pembrolizumab approved as adjuvant treatment following surgical resection and platinum-based chemotherapy for patients with stage IB, II, or IIIA non-small cell lung cancer.

Overall survival data were immature at the time of interim analysis and follow-up will continue to the next analysis.

The biopsy test is the first companion diagnostic approved for entrectinib for individuals who do not have an available tissue sample.

Significant advancements have changed the treatment landscape and clinical practice procedures.

The additional indication expands its therapeutic role beyond advanced non-small cell lung cancer.

Adagrasib (Krazati; Mirati Therapeutics, Inc) approved for adults with KRAS-G12C-mutated locally advanced or metastatic non-small cell lung cancer as determined by an FDA-approved test.

Future research should investigate which therapies with new mechanisms of action add incremental benefit to existing treatment regimens for non-small cell lung cancer.

When used with chemotherapy, pembrolizumab provides a synergistic response to increase survival rates.

Biomarker testing and management of immune-related adverse events are key roles for pharmacists.

Scott Soefje, director of Pharmacy Cancer Care and assistant professor of Pharmacy at Mayo Clinic, discusses the role of PD-1 inhibitors in treating non–small cell lung cancer.

Data from the fourth interim analysis of the ARC-7 trial shows that a combination of Fc-silent anti-TIGIT and anti-PD-1 molecules are effective for objective response rates in certain lung cancers.

Patients with lung cancer in an early-intervention lung screening program were found to have a survival rate nearly 20-times longer than patients with a late-stage diagnosis.